8-K: Bone Biologics Secures $5.0 Million in Public Offering to Advance Clinical Trials and Patent Portfolio

Bone Biologics Corporation has successfully priced and closed a public offering raising $5.0 million in gross proceeds, including common stock and various warrants, to fund clinical trials and expand its patent portfolio.

Summary

• Bone Biologics Corporation priced a public offering on June 27, 2025, and closed it on June 30, 2025.
• The offering included 793,750 shares of common stock and 456,250 pre-funded warrants, totaling 1,250,000 common stock equivalents.
• Each share or pre-funded warrant was accompanied by Series D and Series E warrants, each for an equal number of shares.
• The combined public offering price was $4.00 per share and accompanying warrants, or $3.999 per pre-funded warrant and accompanying warrants.
• Series D warrants have a $4.00 exercise price and expire five years from issuance (June 30, 2030).
• Series E warrants have a $4.00 exercise price and expire 18 months from issuance (December 30, 2026).
• Pre-funded warrants have a nominal exercise price of $0.001 per share and are immediately exercisable until fully exercised.
• Gross proceeds from the offering were $5.0 million, with net proceeds of approximately $4.3 million after deducting placement agent fees and other estimated offering expenses.
• Potential additional gross proceeds from full cash exercise of all warrants could be $10.0 million, though no assurance is given that any warrants will be exercised.
• The company intends to use the net proceeds for clinical trials, patent portfolio maintenance and extension, and general corporate purposes.
• After the closing, Bone Biologics had 1,605,260 shares of common stock outstanding.
• H.C. Wainwright & Co. acted as the exclusive placement agent, receiving an aggregate cash fee of 7.0% of gross proceeds, a 1.0% management fee, and warrants to purchase up to 75,000 shares (6.0% of the aggregate shares and pre-funded warrants sold) at an exercise price of $5.00, expiring June 27, 2030.

Sentiment

Score: 7

Explanation: The successful completion of a public offering, securing $4.3 million in net proceeds and a potential additional $10 million from warrant exercises, provides crucial funding for clinical trials and patent development, which are positive steps for a development-stage biotech company. However, the significant dilution and substantial fees to the placement agent temper the overall positive sentiment.

Positives

• Successfully completed a public offering, raising $5.0 million in gross proceeds, providing essential capital.
• Secured funding for critical strategic initiatives, including clinical trials and the maintenance and extension of its patent portfolio.
• Potential for an additional $10.0 million in gross proceeds if all Series D and Series E warrants are fully exercised on a cash basis, offering future liquidity.
• The offering was conducted under an effective registration statement, indicating compliance with SEC regulations.

Negatives

• The offering involves significant potential dilution for existing shareholders due to the issuance of 1,250,000 shares/pre-funded warrants and an equal number of Series D and Series E warrants, plus Placement Agent Warrants.
• The company incurred substantial fees and expenses for the placement agent, including a 7.0% cash fee, a 1.0% management fee, and warrants for 6.0% of the aggregate shares/pre-funded warrants sold.
• There is no assurance that the potential $10.0 million from warrant exercises will be realized, introducing uncertainty regarding future capital inflow.
• The company is subject to a 60-day prohibition on issuing common stock or equivalents and a one-year prohibition on variable rate transactions, which could limit future financing flexibility.

Risks

• No assurance can be given that any of the Series D or Series E warrants will be exercised, meaning the potential additional $10.0 million in proceeds is not guaranteed.
• The company's ability to raise future capital may be constrained by the 60-day issuance prohibition and one-year variable rate transaction prohibition.
• Additional risks are detailed in the 'Risk Factors' section of the company's Annual Report on Form 10-K filed with the SEC on February 26, 2025, which are not elaborated upon in this document.

Future Outlook

The company intends to use the net proceeds from the offering to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes. The company also aims to continue the listing and trading of its Common Stock on a Trading Market and comply with all related obligations.

Management Comments

• The company intends to use the net proceeds from this offering to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes.

Industry Context

Bone Biologics operates in the orthobiologic products market, specifically focusing on bone regeneration for spinal fusion procedures, with rights also extending to trauma and osteoporosis applications. This capital raise is crucial for advancing its clinical trials, which are a standard and necessary step for product development in the medical device and biotech industries. The funding also supports the maintenance and expansion of its patent portfolio, which is vital for protecting intellectual property and competitive advantage in a highly innovative and regulated sector.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the offering against global benchmarks.
• The use of a public offering with warrants is a common financing mechanism for development-stage biotechnology or medical device companies to raise capital for clinical trials and R&D, reflecting a typical approach in the industry for companies at this stage of development.
• The fees paid to the placement agent (7% cash fee + 1% management fee + warrants) are within the typical range for small-cap public offerings, especially for companies in the biotech sector which often face higher financing costs due to inherent risks and development timelines.

Corporate Governance

Related Party Transactions

• Preemptive rights of Jeffrey Frelick (CEO) and Deina Walsh (CFO) under their employment agreements were irrevocably waived in relation to this offering.

Stakeholder Impact

• Shareholders: Existing shareholders face dilution from the issuance of new shares and warrants. New investors gain exposure to the company's future growth potential.
• Employees: The company's ability to fund clinical trials and maintain its patent portfolio could secure future employment and growth opportunities.
• Customers/Patients: Funding for clinical trials is essential for the development and potential future availability of the company's orthobiologic products.
• Creditors: The capital raise improves the company's financial liquidity and ability to meet its obligations, potentially reducing credit risk.
• Placement Agent (H.C. Wainwright & Co., LLC): Received substantial fees and warrants for their role in facilitating the offering.

Next Steps

• Fund clinical trials for orthobiologic products.
• Maintain and extend the patent portfolio.
• Utilize funds for working capital and other general corporate purposes.
• Maintain listing or quotation of Common Stock on the Nasdaq Capital Market.
• Apply to list all newly issued Shares and Warrant Shares on the Nasdaq Capital Market.
• Comply with reporting, filing, and other obligations under Trading Market rules.
• Maintain eligibility of Common Stock for electronic transfer through Depository Trust Company.

Key Dates

Recommendation

Keywords

Bone Biologics, BBLG, Public Offering, Capital Raise, Warrants, Pre-Funded Warrants, Clinical Trials, Patent Portfolio, Spine Fusion, Orthobiologics, SEC Filing, Form 8-K, H.C. Wainwright & Co.